Schultz J E, Kwok W M, Hsu A K, Gross G J
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
J Mol Cell Cardiol. 1998 Sep;30(9):1817-25. doi: 10.1006/jmcc.1998.0744.
Recent results have shown that the sulfonylurea receptor couples to several types of inward-rectifier potassium (KIR) channels, which suggests that sensitivity to blockade of a pathophysiological phenomenon such as ischemic preconditioning (PC) by glibenclamide may not be the result of this compound selectively blocking the ATP-sensitive potassium (KATP) channel. Therefore, to address this possibility, a role for myocardial KIR v KATP channels in ischemic PC was evaluated in the rat. To test this hypothesis, anesthetized, open-chest, male Wistar rats were assigned to one of seven experimental protocols. Animals assigned to group I (control) received 30 min of occlusion and 2 h of reperfusion. Ischemic PC was produced by 3x5-min occlusion and 2-h reperfusion periods (group II). Terikalant (TK), an inward-rectifier potassium channel blocker, was used to test the role of other K+ channels, most notably the KIR, in the cardioprotective effect of ischemic PC in the rat. TK was given at a dose of 3 mg/kg, i.v., 15 min before the prolonged occlusion and reperfusion periods (group III). In groups IV, V, and VI terikalant (1, 3 and 6 mg/kg, i.v.) was given 15 min before ischemic PC (lowTK+PC, medTK+PC and hiTK+PC, respectively). Group VII consisted of glibenclamide (0.3 mg/kg, i.v.) given 30 min prior to ischemic PC (GLY+PC). Infarct size (IS) as a percent of the area at risk (AAR) was measured using the histochemical stain, 2,3, 5-triphenyltetrazolium chloride. The average IS/AAR for the control was 49.9+/-2.1%. Ischemic PC markedly reduced infarct size (8.6+/-1. 8%; * P<0.05 v control). Terikalant (TK; 1, 3 and 6 mg/kg, i.v.) did not abolish the cardioprotective effect of ischemic PC at any dose (15.5+/-6.4, 16.4+/-5.2 and 8.8+/-1.6%, respectively; * P<0.05 v control). TK itself had no effect on infarct size. GLY completely abolished the cardioprotective effect of ischemic PC (48.2+/-6.4%). In addition, the high dose of TK significantly (P<0.05) increased the action potential duration at 50% repolarization from 48+/-3 to 64+/-4 ms and 30 microM of TK, a concentration which produced a 39% decrease in the inward-rectifier potassium channel current in isolated guinea-pig ventricular myocytes in the whole-cell patch-clamp mode did not block the increase in K ATP current produced by the KATP opener bimakalim (3 microM). These results demonstrate that although the myocardial KATP channel belongs to the K IR superfamily, the endogenous myocardial KIR channel does not mediate ischemic PC in the rat heart; however, the K ATP channel does mediate its cardioprotective effect.
最近的研究结果表明,磺脲类受体与几种内向整流钾(KIR)通道偶联,这表明格列本脲对诸如缺血预处理(PC)等病理生理现象的阻断敏感性可能并非该化合物选择性阻断ATP敏感性钾(KATP)通道的结果。因此,为了探究这种可能性,在大鼠中评估了心肌KIR和KATP通道在缺血预处理中的作用。为了验证这一假设,将麻醉的、开胸的雄性Wistar大鼠分为七个实验方案之一。分配到I组(对照组)的动物接受30分钟的闭塞和2小时的再灌注。通过3次5分钟的闭塞和2小时的再灌注期产生缺血预处理(II组)。使用内向整流钾通道阻滞剂替利卡兰(TK)来测试其他钾通道,尤其是KIR,在大鼠缺血预处理心脏保护作用中的作用。在延长的闭塞和再灌注期前15分钟,以3mg/kg的剂量静脉注射TK(III组)。在IV、V和VI组中,在缺血预处理前15分钟给予替利卡兰(静脉注射,剂量分别为1、3和6mg/kg)(分别为低剂量TK+PC组、中剂量TK+PC组和高剂量TK+PC组)。VII组由在缺血预处理前30分钟静脉注射格列本脲(0.3mg/kg)组成(GLY+PC组)。使用组织化学染色2,3,5-三苯基氯化四氮唑测量梗死面积(IS)占危险面积(AAR)的百分比。对照组的平均IS/AAR为49.9±2.1%。缺血预处理显著减小了梗死面积(8.6±1.8%;与对照组相比,*P<0.05)。替利卡兰(TK;静脉注射,剂量为1、3和mg/kg)在任何剂量下均未消除缺血预处理的心脏保护作用(分别为15.5±6.4%、16.4±5.2%和8.8±1.6%;与对照组相比,*P<0.05)。TK本身对梗死面积无影响。格列本脲完全消除了缺血预处理的心脏保护作用(48.2±6.4%)。此外,高剂量的TK显著(P<0.05)将复极化50%时的动作电位持续时间从48±3毫秒增加到64±4毫秒,并且在全细胞膜片钳模式下,30μM的TK(该浓度使分离的豚鼠心室肌细胞内向整流钾通道电流降低39%)并未阻断KATP开放剂苄甲利明(3μM)所产生的KATP电流增加。这些结果表明,虽然心肌KATP通道属于KIR超家族,但内源性心肌KIR通道并不介导大鼠心脏的缺血预处理;然而,KATP通道确实介导其心脏保护作用。